A large observational study published in BMJ found that patients initiating tirzepatide experienced a 32% lower rate of major adverse cardiovascular events compared to those taking sitagliptin. The cohort tracked nearly 53,000 real-world patients, making it the largest real-world cardiovascular outcome study of tirzepatide to date.
Researchers reported a 2.9% rate of major adverse cardiovascular events — defined as heart attack, stroke, or death from any cause — among tirzepatide users, compared with 4.4% among sitagliptin patients. In absolute terms, approximately one fewer cardiovascular event occurred for every 70 patients who started tirzepatide rather than sitagliptin.
The findings add to a growing body of evidence suggesting GLP-1 receptor agonists may reduce cardiovascular risk beyond their primary use in metabolic disease management. However, because the study was observational rather than a randomized controlled trial, it cannot establish causation.
What happened
Researchers analyzed a real-world cohort of approximately 53,000 patients to compare cardiovascular outcomes between those prescribed tirzepatide and those prescribed sitagliptin. The study was published in BMJ and classified as observational, meaning patients were not randomly assigned to either treatment group.
The primary endpoint was major adverse cardiovascular events (MACE), comprising heart attack, stroke, or death from any cause. Tirzepatide users showed a 2.9% MACE rate versus 4.4% for sitagliptin users, yielding a 32% relative risk reduction. The absolute risk difference translated to roughly one prevented event per 70 patients initiating tirzepatide.
Because the study was not a randomized controlled trial, differences in patient characteristics, prescribing patterns, or follow-up could have influenced the results. As with any observational study, this design provides real-world effectiveness evidence but does not equal proof of causation.
Why it matters
This is the largest real-world cardiovascular outcome study of tirzepatide reported to date. The findings add to evidence from earlier trials such as SURPASS-CV, suggesting that cardiovascular benefits observed in controlled settings may also appear in broader clinical practice — though the observational design means this connection cannot be confirmed as causal.
For prescribers, telehealth providers, and insurance payers, real-world evidence of this scale may influence prescribing decisions and coverage policies. Regulatory authorities could also consider such data when evaluating potential label expansions for cardiovascular risk reduction.
Compounding pharmacies offering tirzepatide and related GLP-1 products may also see downstream effects, as payer and regulatory interest in cardiovascular outcomes could shape demand and compliance expectations.
What to watch next
- Whether regulatory agencies reference this real-world cohort in any future label or indication reviews for tirzepatide.
- How major payers respond to the study in updated coverage criteria for GLP-1 therapies.
- Whether additional observational or randomized studies replicate the 32% relative reduction in different patient populations.
- Any commentary from clinical societies on how real-world evidence should factor into prescribing guidelines.
Sources
Industry information only. Not medical or legal advice.
